Abstract Body

Automated Insulin Delivery systems (AID) have consistently demonstrated improved glycemic outcomes and therefore have been in increasing use for people with Type 1 Diabetes. Pivotal trials have been completed with several systems that are now available for outpatient use. Although women have been adequately represented in these pivotal trials, it is unclear if women have a different glycemic response to AID treatment. A preliminary secondary analysis of AID trials conducted at UVA identified no significant change in hemoglobin A1c or time in range following AID use comparing female and male participants. In terms of changes across the menstrual cycle, there is little information available regarding the impact of AID systems on glycemic control. Preliminary studies have not observed trends in glycemic control or insulin delivery across menstrual cycle phases during AID use, but these studies are small and uncontrolled. Available real-world data will be discussed to consider whether differences are observed between female and male users of AID systems.